Proteinuria due to increased dose of deferasirox in a pediatric patient with thalassemia major: case report


  • Hakan Sarbay Department of Pediatric Hematology and Oncology, Diyarbakir Children Hospital, Diyarbakir, Turkey
  • Mehtap Akbalik Kara Department of Pediatric Nephrology, Diyarbakir Children Hospital, Diyarbakir, Turkey



B-thalassemia, Deferasirox, Proteinuria


Deferasirox is an iron chelator that used in B-thalassemia in worldwide. Nephrotoxicity is one of the common side effects of the deferasirox. Nephrotoxicity can be seen in the form of nephritis and tubulopathy. A 6-year-old male whose ferritin levels were above 3500 ng/mL is reported in this article. Deferasirox was increased from 30 mg/kg/day to 40 mg/kg/day because of the high levels of ferritin. In complete urinalysis of the patient after 3 weeks later +3 protein was detected, and spot urine protein/creatinine ratio was 2.5. In patient without symptoms and findings, deferasirox was discontinued. In his follow-ups, no proteinuria was detected in the complete urinalysis at the second week after the drug treatment was discontinued.


Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-46.

Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120:3657-69.

Aydinok Y, El-Beshlawy A, von Orelli-Leber C, Czarnecki-Tarabishi C, Manz CY. A randomised controlled trial comparing the combination therapy of Deferiprone (DFP) and Desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major. Blood. 2006;108(11):168.

Diaz-Garcia JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Niño MD, Villarrubia J, Ortiz A. Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol. 2014;10:574-86.

Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, et al. Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153:111-7.

Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, et al. Effectiveness and safety of icl670 in ironloaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-602.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-62.

Murtadha Al-Khabori, Bhandari S, Al-Huneini M, Al-Farsi K, Panjwani V, Daar S. Side effects of Deferasirox iron chelation in patients with beta thalassemia major or intermedia. Oman Med J. 2013;28(2):121-4.

Aldudak B, Bayazit KA, Noyan A, Ozel A, Anarat A, Sasmaz I, et al. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000;15:109-12.

Bayhan T, Ünal Ş, Ünlü O, Küçüker H, Tutal AD, Karabulut E, et al. The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation. Hematology. 2017 May;22(4):248-51.

Dubourg L, Laurain C, Ranchin B, Pondarré C, Hadj-Aïssa A, Sigaudo-Roussel D, et al. Deferasirox induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol. 2012;27:2115-22.